Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism

Journal of Clinical Investigation

Volumn 97, Issue 11, 1996, Pages 2509-2516

  Brink, Marijke ^a   Wellen, Jason ^a   Delafontaine, Patrick ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

congestive heart failure; hypertension; IGF binding proteins; metabolism; receptors, growth factor

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DRINKING WATER; HYDRALAZINE; LOSARTAN; MESSENGER RNA; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; DIET RESTRICTION; FEEDING; HYPERTENSION; IMMUNOBLOTTING; MALE; NONHUMAN; NORTHERN BLOTTING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM RESTRICTION; WEIGHT REDUCTION;

EID: 0029890224     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118698     Document Type: Article

References (74)

1. Aquitlera, G., and E.T. Marusic. 1971. Role of the renin angiotensin system on the biosynthesis of aldosterone. Endocrinology. 89:1524-1529.
2. Blantz, R.C., K.S. Konnen, and B.J. Tucker. 1976. Angiotensin H effects upon the glomerular microcirculation and Ultrafiltration coefficient of the rat. J. Clin. Invest. 57:419-434.
3. Hall, J.E. 1986. Control of sodium excretion by angiotensin II: intrarenal mechanisms and blood pressure regulation. Am. J. Physiol. 250:R960-R972.
4. Fitzsimons, J.T. 1980. Angiotensin stimulation of the central nervous system. Rev. Physiol. Biochem. Pharmacol. 87:117-167.
5. Reid, I.A. 1976. The use of saralasin to evaluate the function of the brain renin-angiotensin system. Prog. Biochem. Pharmacol. 12:117-134.
6. Saavedra, J. 1991. Brain and pituitary angiotensin. Endocr. Rev. 13:329-380.
7. Dacmen, M.J., D.M. Lombardi, F.T. Bosman, and S.M. Schwartz. 1991. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ. Res. 68:450-456.
8. Griffin, S.A., W.C. Brown, F. MacPherson, J.C. McGrath, V.G. Wilson, N. Korsgaard, M.J. Mulvany, and A.F. Lever. 1991. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension (Dallas). 17:626-635.
9. Baker, K.M., and J.F. Aceto. 1990. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am. J. Physiol. 259:H610-H618.
10. Powell, J.S., J.P. Clozel, R.K. Muller, H. Kuhn, F. Hefti, M. Hosang, and H.R. Baumgartner. 1989. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science (Wash. DC). 245:186-188.
11. Sadoshima, J.-I., and S. Izumo. 1993. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circ. Res. 73:413-423.
12. Schorb, W., G.W. Booz, D.E. Dostal, K.M. Conrad, K.C. Chang, and K.M. Baker. 1993. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ. Res. 72:1245-1254.
13. Timmermans, P.B., P.C. Wong, A.T. Chiu, W.F. Herblin, P. Benfield, D.J. Carini, R.J. Lee, R.R. Wexler, J.A. Saye, and R.D. Smith. 1993. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45: 205-251.
14. Unger, T., and P. Gohlke. 1994. Converting enzyme inhibitors in cardiovascular therapy: current status and future potential [published erratum appears in Cardiovasc. Res. 1994. 28:435]. Cardiovasc. Res. 28:146-158.
15. The SOLVD Investigators. 1991. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325:293-302.
16. The CONSENSUS Trial Study Group. 1987. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 316: 1429-1435.
17. The SOLVD Investigators. 1992. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 327:685-691.
18. Pfeffer, M.A., E. Braunwald, L.A. Moye, L. Basta, E.J. Brown, Jr., T.E. Cuddy, B.R. Davis, E.M. Geltman, S. Goldman, G.C. Flaker, et al. 1992. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 327:669-677.
19. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. 1994. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and logether on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 343:1115-1122.
20. ISIS-4 Collaborative Group. 1995. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 345:669-685.
21. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. 1993. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:821-828.
22. Alderman, M.H., S. Madhavan, W.L. Ooi, H. Cohen, J.E. Sealey, and J.H. Laragh. 1991. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N. Engl. J. Med. 324:1098-1104.
23. Brunner, H.R., J.H. Laragh, L. Baer, M.A. Newton, F.T. Goodwin, L.R. Krakoff, RH. Bard, and F. R. Buhler. 1972. Essential hypertension: renin and aldosterone, heart attack and stroke. N. Engl. J. Med. 286:441-449.
24. Brunner, H.R., J.E. Sealey, and J.H. Laragh. 1973. Renin as a risk factor in essential hypertension: more evidence. Am. J. Med. 55:295-302.
25. Jones, J.I., and D.R. Clemmons. 1995. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16:3-34.
26. Fryhurg, D.A., L.A. Jahn, S.A. Hill, D.M. Oliveras, and E.J. Barrett. 1995. Insulin and insulin-like growth factor-1 enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. J. Clin. Invest. 96:1722-1729.
27. Delafontaine, P., and H. Lou. 1993. Angiotensin II regulates insulin-like growth factor I gene expression in vascular smooth muscle cells. J. Biol. Chem. 268:16866-16870.
28. Delafontaine, P., X.P. Meng, L. Ku, and J. Du. 1995. Regulation of vascular smooth muscle cell insulin-like growth factor I receptors by phosphorothioate oligonucleotides. Effects on cell growth and evidence that sense targeting at the ATG site increases receptor expression. J. Biol. Chem. 270:14383-14388.
29. Du, J., X.-P. Meng, and P. Delafontaine. 1996. Transcriptional regulation of the insulin-like growth factor I receptor gene by growth factors: evidence for protein kinase C-dependent and -independent pathways. Endocrinology. 137:1378-1384.
30. Ververis, J.J., L. Ku, and P. Delafontaine. 1993. Regulation of insulin-like growth factor I receptors on vascular smooth muscle cells by growth factors and phorbol esters. Circ. Res. 72:1285-1292.
31. Anwar, A., and P. Delafontaine. 1994. Hypertension increases insulin-like growth factor binding protein-4 mRNA levels in rat aorta. Hypertension (Dallas). 24:679-685.
32. Breier, B.H., B.W. Gallaher, and P.D. Gluckman. 1991. Radioimmunoassay for insulin-like growth factor-I: solutions to some potential problems and pitfalls. J. Endocrinol. 128:347-357.
33. Delafontaine, P., K.E. Bernstein, and R.W. Alexander. 1991. Insulin-like growth factor I gene expression in vascular cells. Hypertension (Dallas). 17: 693-699.
34. Delafontaine, P., H. Lou, and R.W. Alexander. 1991. Regulation of insulin-like growth factor I messenger RNA levels in vascular smooth muscle cells. Hypertension (Dallas). 18:742-747.
35. Fort, P., L. Marty, M. Piechaczyk, S. el Sabrouty, C. Dani, P. Jeanteur, and J.M. Blanchard. 1985. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenie family. Nucleic Acids Res. 13:1431-1442.
36. Nelson, D.A., and M.W. Morris. 1991. Basic examination of blood. In Clinical Diagnosis and Management by Laboratory Methods, 18th edition. J.B. Henry, editor. W.B. Saunders, Philadelphia. 553-603.
37. Phillips, P.A., B.J. Rolls, J.G. Ledingham, J.J. Morton, and M.L. Forsling. 1985. Angiotensin II-induced thirst and vasopressin release in man. Clin. Sci. (Colch.). 68:669-674.
38. Ketelslegers, J.-M., D. Maiter, M. Maes, L.E. Underwood, and J.-P. Thissen. 1995. Nutritional regulation of insulin-like growth factor-1. Metab. Clin. Exp. 44(Suppl. 4):50-57.
39. Thissen, J.P., J.M. Ketelslegers, and L.E. Underwood. 1994. Nutritional regulation of the insulin-like growth factors. Endocr. Rev. 15:80-101.
40. Underwood, L.E., J.P. Thissen, S. Lemozy, J.M. Ketelslegers, and D.R. Clemmons. 1994. Hormonal and nutritional regulation of IGF-1 and its binding proteins. Horm. Res. (Basel). 42:145-151.
41. Brink, M., and P. Delafontaine. 1995. Angiotensin II stimulates insulin-like growth faclor 1 gene expression in rat heart. Circulation. 92(Suppl. 1):I-62a. (Abstr.)
42. Fath, K.A., R.W. Alexander, and P. Delafontaine. 1993. Abdominal coarctation increases insulin-like growth factor 1 mRNA levels in rat aorta. Circ. Res. 72:271-277.
43. Donohue, T.J., L.D. Dworkin, M.N. Lango, K. Fliegner, R.P. Lango, J.A. Benstein, W.R. Slater, and V.M. Catanese. 1994. Induction of myocardial insulin-like growth factor-I gene expression in left ventricular hypertrophy. Circulation. 89:799-809.
44. Hanson, M.C., K.A. Fath, R.W. Alexander, and P. Delafontaine. 1993. Induction of cardiac insulin-like growth factor I gene expression in pressure overload hypertrophy. Am. J. Med. Sci. 306:69-74.
45. Wahlander, H., J. Isgaard, E. Jennische, and P. Friberg. 1992. Left ventricular insulin-like growth factor 1 increases in early renal hypertension. Hypertension (Dallas). 19:25-32.
46. Pettinger, W.A. 1980. Minoxidil and the treatment of severe hypertension. N. Engl. J. Med. 303:922-926.
47. Henegar, J.R., G.L. Brower, A. Kabour, and J.S. Janicki. 1995. Catecholamine response to chronic ANG II infusion and its role in myocyte and coronary vascular damage. Am. J. Physiol. 269:H1564-H1569.
48. Crandall, D.L., H.E. Herzlinger, B.D. Saunders, R.C. Zolotor, L. Feliciano, and P. Cervoni. 1993. Identification and characterization of angiotensin II receptors in rat epididymal adipocyte membranes. Metab. Clin. Exp. 42:511-515.
49. Crandall, D.L., H.E. Herzlinger, B.D. Saunders, P. Cervoni, L. Kuzmak, and J.G. Kral. 1993. Angiotensin II receptor binding in rat and human fat cell membranes: effects of growth. Pharmacologist. 35:194a. (Abstr.)
50. Packer, M. 1992. Pathophysiology of chronic heart failure. Lancet. 340: 88-92.
51. Pedersen, E.B., H. Danielsen, T. Jensen, M. Madsen, S.S. Sorensen, and O.O. Thomsen. 1986. Angiotensin II, aldosterone and arginine vasopressin in plasma in congestive heart failure. Eur. J. Clin. Invest. 16:56-60.
52. Schunkert, H., S.S. Tang, S.E. Litwin, D. Diamant, G. Riegger, V.J. Dzau, and J.R. Ingelfinger. 1993. Regulation of intrarenal and circulating reninangiotensin systems in severe heart failure in the rat. Cardiovasc. Res. 27:731-735.
53. Tan, L.-B., J.E. Jalil, R. Pick, J.S. Janicki, and K.T. Weber. 1991. Cardiac myocyte necrosis induced by angiotensin II. Circ. Res. 69:1185-1195.
54. Staroukine, M., J. Devriendt, P. Decoodt, and A. Verniory. 1984. Relationships between plasma epinephrine, norepinephrine, dopamine and angiotensin II concentrations, renin activity, hemodynamic state and prognosis in acute heart failure. Acta Cardiol. 39:131-138.
55. Kuroda, T., and H. Shida. 1983. Angiotensin II-induced myocardial damage with a special reference to low cardiac output syndrome. Jpn. Heart J. 24:235-243.
56. Pittman, J.G., and P. Cohen. 1964. The pathogenesis of cardiac cachexia. N. Engl. J. Med 271:403-409.
57. Carr, J.G., L.W. Stevenson, J.A. Walden, and D. Heber. 1989. Prevalence and hemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 63:709-713.
58. Cohn, J.N., G. Johnson, S. Ziesche, F. Cobb, G. Francis, F. Tristani, R. Smith, W.B. Dunkman, H. Loeb, M. Wong, et al. 1991. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med 325:303-310.
59. Dostal, D.E., and K.M. Baker. 1992. Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Mediation by the AT1 receptor. Am. J. Hypertens. 5:276-280.
60. Geenen, D.L., A. Malhotra, and J. Scheuer. 1993. Angiotensin II increases cardiac protein synthesis in adult rat heart. Am. J. Physiol. 265:H238-H243.
61. Takasaki, I., A.V. Chobanian, R. Sarzani, and P. Brecher. 1990. Effect of hypertension on fibronectin expression in the rat aorta. J. Biol. Chem. 265: 21935-21939.
62. Simon, G., and S. Altman. 1992. Subpressor angiotensin II is a bifunctional growth factor of vascular muscle in rats. J. Hypertens. 10:1165-1171.
63. Simon, G., G. Abraham, and S. Altman. 1994. Stimulation of vascular glycosaminoglycan synthesis by subpressor angiotensin II in rats. Hypertension (Dallas). 23:1148-1151.
64. Crawford, D.C., A.V. Chobanian, and P. Brecher. 1994. Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circ. Res. 74:727-739.
65. Abraham, G., and G. Simon. 1994. Autopotentiation of pressor responses by subpressor angiotensin II in rats. Am. J. Hypertens. 7:269-275.
66. Himeno, H., D.C. Crawford, M. Hosoi, A.V. Chobanian, and P. Brecher. 1994. Angiotensin II alters aortic fibronectin independently of hypertension. Hypertension (Dallas). 23:823-826.
67. Kim, S., K. Ohta, A. Hamaguchi, T. Yukimura, K. Miura, and H. Iwao. 1995. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension (Dallas). 25:1252-1259.
68. Sun, Y., and K.T. Weber. 1993. Angiotensin II and aldosterone receptor binding in rat heart and kidney: response to chronic angiotensin II or aldosterone administration. J. Lab. Clin. Med. 122:404-411.
69. Gronan, R.J., and D.H. York. 1979. Effects of chronic intraventricular administration of angiotensin II on drinking behavior and blood pressure. Pharmacol. Biochem. Behav. 10:121-126.
70. Vari, R.C., S. Zinn, K.M. Verburg, and R.H. Freeman. 1987. Renal nerves and the pathogenesis of angiotensin-induced hypertension. Hypertension (Dallas). 9:345-349.
71. Kabour. A., J.R. Henegar, V.R. Devineni, and J.S. Janicki. 1995. Prevention of angiotensin II induced myocyte necrosis and coronary vascular damage by lisinopril and losartan in the rat. Cardiovasc. Res. 29:543-548.
72. Beck, A., B. Grasmugg, E. Singer, S. Bacher, and G. Raberger. 1985. Angiotensin-induced hypertension in conscious dogs: biochemical parameters and baroreceptor reflex. Cardiovasc. Res. 19:721-726.
73. Werner, H., M. Woloschak, B. Stannard, Z. Shen-Orr, C.T. Roberts, Jr., and D. LeRoith. 1991. The insulin-like growth factor I receptor: molecular biology, heterogeneity, and regulation. In Insulin-Like Growth Factors: Molecular and Cellular Aspects. D. LeRoith, editor. CRC Press, Boca Raton, FL. 17-47.
74. Delafontaine, P. 1995. Insulin-like growth factor 1 and its binding proteins in the cardiovascular system (review). Cardiovasc. Res. 30:825-834.